CLINICAL_TRIALS
trial_result
· 2019-05-22
Clinical Trial Update: Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis [Phase 2]
Summary
Phase 2 trial assessing a lysophosphatidic acid receptor antagonist for idiopathic pulmonary fibrosis has completed with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bristol-Myers Squibb | Conditions: Idiopathic Pulmonary Fibrosis | Phase 2 | Status: COMPLETED | Results posted: 2019-05-22